|
DecImmune Therapeutics is developing novel peptides and antibodies for acute, tissue damaging inflammation in myocardial infarction, burns, and other conditions involving vascular injury and reperfusion. The company's approach is based on the discovery in the laboratories the company's founders at Harvard Medical School, Michael Carroll, PhD, and Francis Moore Jr., MD, of the N2 pathway, the dominant innate immune mechanism that initiates the immune and inflammatory responses in these conditions. The company's lead program, in advanced preclinical development, is for the treatment of myocardial infarction. |
02.26.2013DecImmune Therapeutics Secures $2.25 Million in Development Funding |
